Five-year impact of repeated praziquantel treatment on subclinical morbidity due to Schistosoma japonicum in China by Li, Y.S. et al.
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE (2002) 96,438-443 
Five-year impact of repeated praziquantel treatment on subclinical morbidity 
due to Schistosoma japonicum in China 
Y. S. Lily*, A. C. Sleigh’, Y. Li*, M. Tanner3, A. Dessein4, G. M. Willlams’ and D. P. McManus’ ‘Tropical 
Health Programme, Australian Centre for International and Tropical Health and Nutrition, The Queensland Institute of 
Medical Research and The University of Queensland, 300 Herston Road, Herston, Brisbane, Queensland 4029, Australia; 
‘Hunan Institute of Parasitic Diseases, Huabanqiao Road, Yueyang, Hunan 414000, The People’s Republic of China; 3Swiss 
Tropical Institute, Socinstrasse 57, I? 0. Box Ch-4002, Basel, Switzerland; “Faculty of Medicine, INSERM U 399, 
Immunology and Genetics of Parasitic Diseases, Marseille, France 
Abstract 
We report the 5-year impact (1996-2001) of repeated praziquantel chemotherapy on subclinical 
morbidity related to Schistosoma japonicum infection. We repeated stool examinations and hepatosplenic 
ultrasonography in a cohort of 120 individuals living on an island with endemic infection in Dongting 
Lake, China. Prevalence of schistosome infection fell by 43% and intensity (geometric mean eggs per 
gram) declined by 80% over the 5 years. However, transmission persisted at a dangerously high rate of 
13% per year for re-infection or new infection in the cohort. The prevalence of left-lobe enlargement and 
dilated portal vein fell significantly (P < 0.01) to about half initial levels although a few patients 
progressed during the study period. At study endpoint, infection was nearly twice as common if the 
portal vein was dilated (23% versus 13%, respectively), but this association was not statistically 
significant (P > 0.05). However, endpoint infection was even more strongly associated with left-lobe 
enlargement (57% versus 15%, P < 0.01). The proportions of subjects with improved parenchymal and 
periportal tibrosis were much higher than the proportions of subjects that progressed (P < 0.05). 
Reduction of prevalence and intensity of infection, and improvement of subclinical morbidity, were 
benefits of repeated treatments. Further research is needed to understand why some patients developed 
fibrosis despite substantial reductions in egg counts and to evaluate the functional importance of residual 
subclinical morbidity after chemotherapy-based control in the lake and marshland area of China. 
Kevwords: schistosomiasis, Schistosoma j ponicum, re-infection, morbidity, chemotherapy, praziquantel, ultrason- 
ography, China 
Introduction 
Schistosoma japonicum causes the most severe pathol- 
ogy of the 3 major schistosome species infecting hu- 
mans (CHEN 8z Mom, 1988). Despite great strides for 
controlling schistosomiasis over the past 4 decades in 
the People’s Republic of China, infection still affects 
about one million people in this country, with most 
patients being concentrated in the lake and marshland 
regions (CHEN & FENG, 1999; LI et al., 2000a, 2000b; 
YUAN et al., 2000). Historically, the disease had a 
devastating effect on the public health of people in 
endemic areas. Chronically infected patients developed 
liver fibrosis with portal hypertension, frequently result- 
ing in life-threatening upper-gastrointestinal haemor- 
rhage. Today, infection persists and some people still 
get severe disease, although less commonly than before. 
Effects on economic production, learning capacity and 
childhood growth remain major problems (LI et al., 
1993; MCGARVEY et al., 1993; NOKES et al., 1999). 
Praziquantel remains the drug of choice for treatment 
of established S. japonicum infection although arte- 
mether and artesunate are known to have useful pro- 
phylactic effects against recent S. japonicum infection 
(XIAO et al., 2000; ROSS et al., 2001). Praziquantel is 
safe and can be administered orally in a single dose. 
Thus, it has become the basis of the major control 
strategy for schistosomiasis in endemic areas through 
community-based chemotherapy programmes. Para- 
sitological cure rates achieved by praziquantel in China 
are still 80-90% (LI et al., 2000a, 2000b; YU et al., 
2001) and there is no evidence of resistance in China 
although this drug has been used widely to control 
schistosomiasis for more than 15 years. Clinical mor- 
bidity attributable to S. japonicum infection can be 
reduced and prevented by use of periodic chemotherapy 
(WIEST et al., 1991; OHMAE et al., 1992; OLVEDA et al., 
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1996; ROSS et al., 1998). However, the long-term public 
health importance of chemotherapy on subclinical S. 
japonicum morbidity, detected by ultrasonography, re- 
mains unclear (LI et al., 2000a, 2000b; CAI et al., 1997). 
Usually, more than half of the chronic cases of 
schistosomiasis are asymptomatic, and many clinical 
symptoms and signs related to S. japonicum infection 
are non-specific. Ultrasonography is a safe and rapid 
tool and it has been proposed as an approach to 
examine hepatic fibrosis-induced by Schist&ma infec- 
tion since the 1970s (HATZ. 2001). Most studies have 
reported decreases in portal vein ‘enlargement and in 
echogenic bands after effective treatment (HOMEIDA 
et al., 1988; DOEHRING et al., 1989; MOTT et al., 1992; 
WIE~T et al., 1993; BOISIER et al., 1998; LI et al., 
2000a. 2000b). Recentlv. we reoorted subclinical 
changes in a community ’ cohort in Dongting Lake 
exposed to endemic S. iaponicum infection from before 
praziquantel treatment to 2 years after therapy (LI 
et al.. 2000a. 2000b). Here we describe the 5-vear 
impact of repeated chemotherapy on endemic S. japo- 
nicum infection and associated subclinical morbidity in 
the same longitudinal cohort of 120 residents in the 
Dongting Lake region of China. 
Materials and Methods 
Study area 
This study involved 5 villages on 2 islands (Qingshan 
and Niangashan) in the Dongting Lake, Hunan Prov- 
ince. China. This is a moderatelv endemic area for 
schistosomiasis but is not endemic for malaria. Control 
programmes including praziquantel chemotherapy for 
humans were established in the 1990s. However, due 
to uncontrolled infection sources, re-infection after 
drug therapy is frequent and the overall prevalence of 
infection for humans in the 2 islands remains stub- 
bornly at 15-20% (LI et al., 1997; ROSS et al., 1998). 
Study design 
Full details of the longitudinal study design are 
described by LI et al. (19997. In brief, we screen&l 72% 
(n = 1909) of the residents of the study area for active 
schistosome infection by stool examination, and for 
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continuing water exposure or past infection by ques- 
tionnaire. A total of 250 individuals (160 subjects from 
Qingshan and 90 from Niangashan) were currently 
exposed and had past or present infection. They were 
selected for a 5-vear longitudinal studv in 1996. All 
250 subjects, whether found infected (n = 75) or not 
(n =175) at baseline stool examination, received a 
single dose (40 mg/kg) of praziquantel (Shin Poong 
Pharmaceutical Co., Ltd, Seoul, South Korea) and 
ultrasound assessment at the beginning of the study. 
Seven weeks after treatment, the stool examination was 
repeated and those still positive (n = 13) were re- 
treated. Thus, all egg-positive subjects were cured at 
the start of study. 
Two years post-treatment the study subjects initially 
selected had further parasitological and ultrasound as- 
sessment and were again offered a single dose (40 
mg/kg) of praziquantel treatment. Unfortunately, soon 
after that the islands suffered greatly as a result of major 
flooding of the Yangtze River and Dongting Lake in 
August 1998. The residents of Niangashan abandoned 
the island to rebuild houses near a small township close 
to the shore of Dongting Lake. Because these island 
residents moved out of our study area and substantially 
changed their occupations with much less water ex- 
posure, they were excluded from this study. Thus our 
follow-up examinations in 2000 and 2001 were re- 
stricted to those living on Qingshan island for the next 
3 years. 
In May 2000, 131 subjects still living on the larger 
island (Qineshan) were aeain offered a single dose of 
praziqua&ei. In June 2001; 5 years after the;tart of the 
study, 120 of these residents (original n = 160) pro- 
vided complete data for 3 treatments and 3 parasito- 
logical and ultrasound assessments. In addition, current 
alcohol intake (none, occasionally, frequently, daily 
and intoxicated at times) and water exposure (none, 
l-2 times/month, 1-2 times/week) in the previous 
2 months were recorded by a questionnaire. 
infection assessment 
Each subject was asked to provide 2 stool samples for 
parasitological examination in 1996, 1998 and 2001. 
For each stool sample, three 41.7-mg Kato-Katz thick 
smears were prepared; thus every subject had 6 smears 
for each assessment. The presence of S. japonicum eggs 
was confirmed independently by 2 microscopists from 
Hunan Institute of Parasitic Diseases, China. 
Ultrasound measurements 
All ultrasound measurements were conducted on 
subjects in 1996, 1998 and 2001 by the same experi- 
enced observer to reduce measurement bias that could 
arise with different technicians at multiple time-points. 
The examiner was blinded to all other results and 
was unaware of the underlying study hypotheses. The 
equipment used was a portable ultrasonograph (Sono- 
layer L SAG33B; Toshiba, Tokyo, Japan). Measure- 
ments, classifications, standard positions and views 
followed the WHO standards established in Cairo in 
1990 (see Cairo protocol by JENKINS & HATZ, 1992). 
Photographs and a description of the parenchymal 
fibrosis stages for schistosomiasis japonica that have 
been used in China for many years can be found in 
ROSS et al. (2001) and are defined as: 
stage I fibrosis, focal echodense areas scattered within 
the liver parenchyma with absence of definite borders; 
stage II fibrosis, stronger light bands forming a ‘fish- 
scale’ pattern, and a few focal echodense areas 
>20 mm in diameter; 
stage III fibrosis, echodense bands forming a contigu- 
ous network, multiple focal echodense areas >20 mm 
in diameter and masses with central fibrosis. 
Periportal fibrosis was also based on the same stan- 
dards: the average of the out-to-out measurements of 
3 periportal branches of the portal vein were used 
for recording purposes: I = 3-5 mm, II = 6-7 mm, 
III > 7 mm. ‘Enlargement of spleen’ was defined as 
>lOO mm. 
Statistical analysis 
Statistical software (SPSS, Inc., Chicago, IL, USA) 
was used for data processing and analysis. Infection 
intensity (eggs per gram of faeces; epg) among the 
infected sub-groups was expressed as geometric means 
(+ geometric SD). Relative frequencies were compared 
by the x2 test, or McNemar’s test for paired analyses. 
Differences with a P value CO.05 were considered 
statistically significant. Cohort data analysis compared 
results for 1996 and 2001. Subclinical data of this study 
before (1996) and 2-years post-treatment (1998) were 
recently published (LI et al., 2000a, 2000b). 
Ethical considerations 
This study was approved by the medical ethics com- 
mittees of Hunan Province in China, the University of 
Queensland and Queensland Institute of Medical Re- 
search in Australia. Treatment once every 2 years for 
schistosomiasis control in endemic areas like those 
involved in this study is recommended by the Chinese 
National Control Programme (LI et al., 1999). 
Results 
Among the 120 cohort individuals studied in 2001, 
79.2% were male, 85% were adults (aged >20 years) 
and the mean age was 39 i 13.1 years (range 9- 
65 years). Overall, 91% (n = 109) had had water con- 
tact in the previous 2 months; 25.7% of these recently 
exposed subjects reported contact with lake water 
weekly due to work activities. Few cohort members 
reported frequent alcohol intake (only 6 subjects) so we 
could not explore its influence on liver disease in this 
cohort. 
The initial prevalence and intensity (mean f SD) of 
S. japonicum infection among the infected patients in 
the cohort in 1996 was 25.8% (n = 31) and 295 f 3.4 
epg, respectively. Two years after the first treatment in 
1996 the prevalence and intensity of infection (1998) 
were 208% and 95 * 5.6 epg, respectively. At the end 
of the study in 200 I, the prevalence and intensity in the 
cohort were 14.2% and 58 5 2.4 epg. Overall, 28.1% 
(n = 25) of 89 non-infected subjects at the commence- 
ment of the study got a new infection during the 
5 years; 37.0% (n = 17) of 46 subjects initially infected 
in 1996 or 1998 were re-infected before 2001 (Figure). 
Of 17 infected individuals in 2001, 10 subjects had not 
previously been detected as infected in 1996 and 1998. 
The yearly incidence of new infection plus re-infection 
remained dangerously high (13%). Compared with the 
1996 baseline data, the human prevalence fell 43% and 
geometric mean intensity of infection fell 80% owing to 
chemotherapy applied 3 times over 5 years. 
Parenchymal abnormalities 
Parenchymal fibrosis (stage II or III) was detected by 
ultrasound in 38.3% of the cohort (46/120) in 1996 
and this prevalence declined to 29.2% (n = 35) by 
2001 (Table l), a substantial but not significant fall 
(P > 0.05). We observed the evolution of parenchymal 
features of subjects from 1996 to 2001 and found that 
fibrosis staging after treatment did not change in 68.3% 
(n = 82) of individuals; however, 11 of those with stage 
I or II progressed (lo%, 1 l/105) and 27 of the 46 
patients with stage II or III improved (59%, 27/46) 
(Table 2). Stage II and III parenchymal fibrosis in 
2001 was not related to current infection status (P> 
0.05). However, the evolution of parenchymal fibrosis 
was strongly associated with current infection; 55% 
(6/l 1) of those with progressive fibrosis had current 
infection, in contrast to only 12~5% (1 l/88) of others 
(P < 0.01). 




Figure. Infection, new infection and re-infection with Schistosoma japonicum in a cohort of 120 subjects in 1996, 1998 and 2001 from 
the Dongting Lake region of China. Treatment with praziquantel was given at the start of the study (1996) and in 1998 and 2000. 
Table 1. Parenchymal measurement in a cohort Table 3. Periportal grading of a cohort of 120 
of 120 subjects, from the Dongting Lake region, subjects in Dongting Lake region, China, in 1996, 
China, in 1996,199s and 2001 1998 and 2001 
Parenchyma 1996 1998 2001 
grading % (n) % (n) % (72) 
ro 
9.2 (11) 11.7 (14) 20.8 (25) 
52.5 (63) 625 (75) 50.0 (60) 
::r 
25.8 (31) 20.8 (25) 20.8 (25) 
12.5 (15) 5.0 (6) 8.3 (10) 
Fibrosis 1996 1998 2001 
grading % (n) % (n) % (n) 
I” 79.2 (95) 87.5 (105) 74.2 (89) 
::I 
19.2 (23) 10.8 (13) 19.2 (23) 
1.7 (2) 1.7 (2) 6.7 (8) 
“Grades 0 and I were combined. 
Periportal abnormalities 
Periportal fibrosis (stage II or III) was found in 
20.8% (25/120) of the cohort in 1996, and in 25.8% 
(31/120) at the end of the study in 2001 (P > 0.05) 
(Table 3); 73.3% (n = 88) had no changes in periportal 
fibrosis. Periportal fibrosis progressed in 17.8% of the 
subjects (21/118), but 47.8% (n = 11/23) identified 
initially with periportal fibrosis stage II improved by 
2001 (P < 0.01) (Table 4). The 2 patients with peri- 
portal fibrosis stage III in 1996 did not improve during 
the 5-year study. Another 6 individuals (4/6 without 
current infection) developed periportal fibrosis stage 
III. Periportal fibrosis was not related to current infec- 
tion in 2001 (P > 0.05). 
parameters were compared. However, a low coinci- 
dence for fibrosis II (57.5%) and III (53%) was evi- 
dent. 
Portal vein dilation and left-lobe and spleen enlargement 
Coincidence between parenchymal and pertportal grade 
measured in 2001 
Measurement of both parenchymal and periportal 
fibrosis evaluates overall liver fibrosis. A high coinci- 
dence (79.3%) was noted between grading 0 or I of 
parenchymal and periportal fibrosis in 200 1 when the 2 
A dilated portal vein (212 mm inner-wall diameter) 
in 1996 and 1998 was recorded in 19.2% (n = 23) and 
12.5% (n = 15) of the cohort, respectively; by 2001 the 
prevalence had fallen to 10.8% (n = 13). There was no 
statistical significance of portal vein dilatation preva- 
lence from 1996 to 2001 (P > 0.05). However, of 23 
persons who previously had a dilated portal vein at 
baseline (1996) 35% (n = 8) improved by the end of 
the study; another 3.1% (3/97) progressed to develop a 
dilated portal vein (P < 0.05), with no current infec- 
tion. Current dilated portal veins were not substantially 
associated with re-infection (P > 0.05); 23% (3/13) of 
patients with dilated portal vein had infections in 2001 
compared to 13% (14/107) of those with no dilated 
portal vein. Ascites was not detected in any individual 
in the cohort. 
Table 2. Dynamics of parenchyma grading in a cohort of 120 subjects in 
Dongting Lake region, China, in 1996 and 2001 
Parenchyma 




Parenchyma grading 2001 
Total Progressed Improved 
I” II III (n) (%I (%) 
64 17 13 6 4 
8”; 6 : 
74 31 10.5 3.2 54.8 - 
15 
25 10 120 (nrll) 
66.7 
(n = 27) 
“Grades 0 and I were combined. 
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Table 4. Dynamics of periportal grading in a cohort of 120 subjects in 
Dongting Lake region, China, in 1996 and 2001 
Periportal grading 200 1 
Periportal Total Progressed Improved 
grading 1996 I” II III (n) W) (%I 
I” 78 15 2 95 17.9 - 
II 11 8 4 23 17.4 47.8 
III 
8: 
0 2 2 
Total (n) 23 8 120 (n Z-21) (2 11) 
“Grades 0 and I were combined. 
Left-lobe enlargement was detected in 24.2% (n = 
29) of the cohort in 1996 but this fiaure was sianifi- 
cantly reduced to 11.7% (n = 14) by 2001 (P< 601). 
Although 7~7% (7/91) of individuals without left-lobe 
enlargement in 1996 developed it by 2001, 76% 
(22/29) of baseline left-lobe enlargement subjects im- 
proved (P < 0.01). Development of left-lobe enlarge- 
ment was related to .S. juponicum infection (P < 0.01); 
57% (4/7) of patients with left-lobe enlargement had 
endpoint infection, compared to only 15% (13/84) of 
those with a normal left lobe. 
Splenomegaly occurred in only 5.8% (n = 7) of the 
cohort in 1996, and 4.2% (n = 5) in 2001 (P > 0.05). 
Of the 7 baseline splenomegaly cases, 5 improved after 
treatment; the 2 patients with persistent splenomegaly 
were aged >64 years and were uninfected in 2001. 
However, 3 subjects (aged >50 years) developed sple- 
nomegaly in 2001; 2 were infected only in 1996 and 
one had an infection in 1998 and a re-infection in 
2001. 
Discussion 
Previous studies have demonstrated that the preva- 
lence and morbidity of schistosomiasis japonica de- 
crease over time after implementation of successful 
population-based chemotherapy programmes (OLVEDA 
et al., 1996; Ross et al., 1998; CHEN & FENG, 1999; 
YUAN et al., 2000). This success is due to a decrease in 
average human worm burdens and may also reflect a 
transmission decline in the number of infected humans 
contributing eggs into the environment. In our study, 
prevalence declined by 43.4% (25.8% to 14.6%) and 
infection intensity fell by 80% (295 epg to 58 epg) 
following chemotherapy given 3 times over 5 years. 
Overall, this chemotherapy-based intervention reached 
the goal of a 40% reduction of infection established for 
national control by the World Bank-China Schisto- 
somiasis Control Programme (YUAN et al., 2000). The 
strategy of chemotherapy at 2-year intervals in endemic 
areas typified by the lake and marshlands in the Dong- 
ting Lake region reduces both prevalence and infection 
intensity, but transmission of infection in this area 
certainly continues. We found a 13% rate of re-infec- 
tion or new infection per year in our at-risk cohort. 
This might be explained by the fact that the transmis- 
sion of S. juponicum is maintained by migrating tisher- 
men living on the lake combined with the existence of 
non-human reservoirs, especially water buffaloes. Fre- 
quent m-infection after treatment blunts the impact of 
chemotherapy-based control and both people and pro- 
gramme staff become less enthusiastic over time. 
Ultrasound is a safe, rapid, non-invasive and 
relatively inexpensive technique for assessing schisto- 
somiasis-related lesions in individual patients and in 
community surveys (ABDEL-WAHAB et al., 1990; 
HATZ, 2001). Moreover, it provides an opportunity to 
visualize the evolution of pathological lesions after 
effective treatment. We used this technique to stage 
fibrosis at the beginning and end of our 5-year study. 
Left-lobe enlargement and dilated portal vein were 
considerably less common in the cohort in 200 1 than in 
1996. Although the prevalences of parenchymal and 
periportal fibrosis II or worse were not significantly 
reduced statistically, the percentage of improvement 
was much greater than that of progression. Paren- 
chymal fibrosis and left-lobe enlargement progressed in 
association with current infection, but not progression 
of nerinortal fibrosis and dilated oortal vein. This SUP- 
gests that left-lobe enlargement -and abnormalities Gf 
the liver parenchyma in this cohort may be due mainly 
to granulomatous inflammatory host responses to schis- 
tosome eggs trapped in the perisinusoidal spaces of the 
liver. Given the study design and the examinations 
undertaken, we cannot completely exclude other patho- 
genic agents, such as chronic hepatitis B and alcoholic 
liver disease (LI et al., 2000a). 
Improvement of left-lobe enlargement and abnorm- 
alities of parenchymal features after chemotherapy is 
attributable to treatment benefits. It seems that im- 
provement of parenchymal fibrosis was more respon- 
sive to treatment than periportal fibrosis. Parenchymal 
abnormalities are recognized as the most common and 
distinctive findings for S. juponicum infection. It is 
interesting that co-morbidity with severe parenchymal 
fibrosis and severe periportal fibrosis was relatively 
uncommon in this cohort, which might reflect the dif- 
ferent pathobiology or host susceptibility for these 
lesions, or both. A study of S. juponicum infections in 
the Philippines recently described 2 types of liver lesion 
as detected by Doppler ultrasonography (KARDORFF 
et al., 1999). The first, a typical periportal fibrosis 
reduced portal venous blood flow velocity; the second, 
a fibrous network, anatomically separated from the 
portal branch, was not associated with changes in portal 
venous blood flow, but with cholestasis and enzyme 
changes indicative of liver damage. In our previous 
study of this Chinese cohort (LI et al., 2000a) we 
reported that serum concentrations of hyaluronic acid, 
a glycosaminoglycan mainly synthesized by hepatic 
stellate cells and taken up and degraded almost exclu- 
sively in hepatic sinusoidal endothelial cells, were re- 
lated to re-infection and severe parenchymal fibrosis 
but not to periportal fibrosis and dilated portal vein. 
The interpretation of ultrasound imaging depends 
somewhat on the experience of the investigators. 
Therefore, a protocol for standardizing scan proce- 
dures, reducing observer variation for organ measure- 
ments and integrating the grading system of fibrosis 
with other observation of left-lobe and portal vein 
enlargement, is required to compare results from differ- 
ent settings. As the new standard proposed by World 
Health Organization to stage ultrasound observations 
has so far been developed only for assessing pathology 
induced by S. huemutobium and S. mansoni (HATZ, 
2001), we had to use the original (unrevised) WHO 
Cairostandards (JENKINS&HATZ, 1992). 
Only 15% of subjects were aged <20 years in this 
study because our cohort participants were from a very 
remote island and younger people migrate out for 
school and work. This limited our capacity to study 
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age-related subclinical morbidity. However, severe peri- 
portal fibrosis was seen less commonly in patients 
younger than 36 years old, and parenchymal abnormal- 
ities occurred less commonly in patients younger than 
20 years old in our previous study (LI et al., 2000a), 
suggesting long-standing infection is needed to induce 
the most severe form of liver fibrosis. 
Hepatosplenic disease (advanced schistosomiasis) in- 
duced by schistosomes is characterized by periportal 
liver fibrosis, spleen enlargement and congestion, portal 
vein hypertension, and other serious sequelae. These 
are the end result of CD4+ T-cell-dependent granulo- 
ma formation, caused by live parasite eggs lodged in 
hepatic portal venules (ROSS et al., 2001). Infection 
prevalence and intensity do not show a stable correla- 
tion with each other in areas that have had regular 
population treatments, and mean intensity is then the 
most reliable (but still imperfect) predictor of disease. 
Genetic variants among humans have been reported 
to influence the development of severe disease. In stud- 
ies on S. munsoni, Dessein and his colleagues have 
identified several genomic regions (5q31-q33, 6q22- 
q23, lp21-q23, 6p21 -q21) that may be associated 
with infection intensity or clinical manifestation (MAR- 
QUET et al., 1996, 1999; DESSEIN et al., 1999; ZINN- 
JUSTIN et al., 2001). In China, an association between 
susceptibility to schistosomal hepatic fibrosis and 
HLA-DR-DQ alleles has been demonstrated (HIRAYA- 
MA et al., 1999; ROSS et al., 2001), reflecting a possible 
genetic basis for the disease. In our study area, although 
effective praziquantel treatment had been given to 
all participants several times, hepatic morbidity still 
progressed in a few subjects even without recent re- 
infection. We are not sure whether the patients who 
progressed are associated with some genetic effect. In 
addition, a questionnaire we used to collect family 
history of advanced schistosomiasis (data not shown) 
revealed that 3 of 15 patients having hepatic fibrosis 
stage III had records of ascites and &t&ant spleno- 
meealv in their familv uediarees. Whether severe liver 
fib&h induced by 9 $&&u, infection is linked to 
genetic factors is currently under study in the Dongting 
Lake region. In addition, there is a need to establish 
more clearly the functional significance and thus the 
impact of subclinical morbidity in S. japonicum, in 
order to capture the full public health importance of 
the disease in these endemic settings. It is known there 
are 3.2 million people still at risk of schistosomiasis in 
the Dongting Lake region, with an average infection 
prevalence of 10% (LI et uZ., 2000b). Applying our 
endpoint prevalence of parenchymal morbidity (29%) 
to the infected population just in this region (320 000) 
we can estimate that 93000 people would still have 
subclinical disease despite optimal periodic treatment. 
To control schistosomiasis in an endemic area such 
as Dongting Lake much still needs to be done. First, 
chemotherapy should be repeated and focused on those 
with high water exposure after using a questionnaire to 
determine those most at risk. For instance, the preva- 
lence of human infection and re-infection probably 
reaches 20-30% at maximum in this area, but another 
70% of individuals without infection were also treated. 
With limited financial resources for schistosomiasis 
control and potential drug resistance, chemotherapy 
could be replaced by targeted chemotherapy even when 
the prevalence is relatively high (> 15%). Similarly, the 
application of molluscicides could focus on the high 
concentrations (‘hot-spots’) of snails before the trans- 
mission season. Health education as a complementary 
approach will improve the residents’ knowledge and 
behaviour for self-protection. Ecological measures to 
reduce such occupational exposure should be a priority 
in the lake and marshland region of China. As well, 
anti-fecundity and anti-disease vaccines, once devel- 
oped and validated, will become important comple- 
ments of the currently prevailing control strategies. 
Y. S. LI ETAL. 
Finally, the genetic basis of residual subclinical morbid- 
itv, and its functional imnact on nublic health in the 
lake and marshland area of China deserve further 
research. 
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